From Medscape Oncology

Medscape Medical News from the:

American Society of Hematology (ASH) 55th Annual Meeting

December 07 - 10, 2013; New Orleans, Louisiana

This coverage is not sanctioned by, nor a part of, the American Society of Hematology.

Meeting Highlights at a Glance

Top News From ASH 2013: Slideshow
Highlights include new promise with CAR-engineered T-cells for leukemia and lymphoma, a potentially disease-modifying drug for myelofibrosis, and novel targeted therapies for CLL.

Conference News

Medscape Oncology©  WebMD, LLC

Medscape Oncology Insights

Off and On Again Story of Ponatinib in CML
Michael Deininger, MD, PhD

Is Obinutuzumab the Drug to Watch in CLL?
Bruce D. Cheson, MD;
Myron S. Czuczman, MD

Novel Agents: Making the Benefit Last in CLL
Bruce D. Cheson, MD;
Susan M. O'Brien, MD

Idelalisib Raises Eyebrows in Lymphoma
Bruce D. Cheson, MD;
Gilles Salles, MD, PhD

CLL Combos: And the Winner Is...
Bruce D. Cheson, MD;
Clemens M. Wendtner, MD

Tailoring CLL Treatment to a TTT
Michael Hallek, MD;
Alice Goodman, MA

Pre-Meeting Expert Commentary

ASH 2013: Big Year for CLL, Lymphoma
Bruce D. Cheson, MD